Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Social Anxiety Disorder (SAD) Clear all
Recruiting Phase 2 Interventional

A Study of NTX-1472 in Social Anxiety Disorder

NCT07323784
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
NTX-1472, Placebo
Drug
Lead sponsor
Newleos Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Encino, California • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Generalized Anxiety Disorder and Social Anxiety Disorder: Their Impact on the Processing of Information and Learning

NCT00062517
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
497 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

Geodon for the Treatment of Refractory Social Anxiety Disorder

NCT00215150
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Ziprasidone, Sertraline
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 4 Interventional

Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder

NCT00208741
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Gabitril
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
3
States / cities
Atlanta, Georgia • Long Island City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2013 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

NCT07221578
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
VQW-765, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
30
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional Results available

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

NCT01470469
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
Interventions
SPD503 (extended-release Guanfacine hydrochloride), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Birmingham, Alabama • Carson, California • Imperial, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Individual Factors of CBT Underlying Success

NCT06678295
View directory record Official record
Conditions
Social Anxiety Disorder, Body Dysmorphic Disorder
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

NCT06615557
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Not listed Not applicable Interventional

Study of Vilazodone to Treat Social Anxiety Disorder

NCT01712321
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Vilazodone, Placebo
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Not applicable Interventional

Stepped Care Treatment for Anxiety Resilience

NCT07228143
View directory record Official record
Conditions
Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Separation Anxiety Disorder, Specific Phobia, Obsessive Compulsive Disorder (OCD), Panic Disorder (With or Without Agoraphobia)
Interventions
Relaxation and Mentorship Training (RMT), Stepped Care Targeting Exposure and Parenting for Anxiety (STEP-A)
Behavioral
Lead sponsor
Andrew Wiese
Other
Eligibility
7 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

NCT07193563
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
ENX-102, Placebo
Drug · Other
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Withdrawn Phase 1 Interventional

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

NCT05429788
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Low dose RLS103, High dose RLS103, placebo inhaled dry powder
Drug
Lead sponsor
Receptor Life Sciences
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Los Angeles, California • Oceanside, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 4 Interventional Results available

A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder

NCT03078270
View directory record Official record
Conditions
Anxiety Disorder Social, Anxiety
Interventions
botulinum toxin A, Placebo
Drug · Other
Lead sponsor
Daniel Lieberman
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Results available

Computer-Based Treatment for Social Anxiety Disorder

NCT03415022
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
computer-based treatment
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 4 Interventional

Cariprazine Versus Placebo for Social Anxiety Disorder

NCT05384483
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
The Medical Research Network
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 1 Interventional

A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline

NCT05189977
View directory record Official record
Conditions
Post-traumatic Stress Disorder (PTSD)
Interventions
Propranolol, Prazosin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jul 21, 2026, 11:01 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)

NCT05030350
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Watertown, Massachusetts • New York, New York • Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Phase 3 Interventional

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

NCT02622958
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
PH94B, Placebo
Drug · Other
Lead sponsor
Pherin Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Not applicable Interventional Results available

A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

NCT06037668
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
BVR-100, BES-100
Device
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Orlando, Florida • Boston, Massachusetts • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Jul 21, 2026, 11:01 AM EDT
Completed Early Phase 1 Interventional Results available

Ketamine Infusion for Social Anxiety Disorder

NCT02083926
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Jul 21, 2026, 11:01 AM EDT
Withdrawn Not applicable Interventional

Waitlist-Control Trial of Smartphone (App-based) CBT for Social Anxiety Disorder (SAD), Withdrawn

NCT04622930
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Smartphone-delivered CBT for SAD
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

NCT06809179
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Sherman Oaks, California • Walnut Creek, California • Largo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 11:01 AM EDT
Suspended Not applicable Interventional

A Novel Computer-Based Therapy for Social Anxiety

NCT03240003
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
GC-MRT, modified GC-MRT, Non-GC-MRT
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 21, 2026, 11:01 AM EDT